Zhenyu Xu Sells 2,700 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Zhenyu Xu sold shares under a pre-arranged Rule 10b5-1 plan — 2,700 shares on April 6 at $4.85 (plus recent sales of 2,400 on April 7 and 608 on March 19) to cover tax withholding tied to vested equity, leaving him with 647,352 shares (a 0.42% ownership decrease).
• SOPHiA GENETICS stock traded at $4.89 with a market cap of $334.6M; the company reported a quarterly loss of $0.28 per share (missing estimates by $0.08) and shows negative profitability metrics (net margin -44.22%, negative ROE).
• Analyst sentiment is mixed with a consensus rating of Hold and a consensus price target of $7.00 (two Buys, one Sell), including $7 targets from Guggenheim and BTIG while Weiss Ratings maintained a Sell.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 2,700 shares of the company's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $4.85, for a total value of $13,095.00. Following the completion of the sale, the insider owned 647,352 shares in the company, valued at $3,139,657.20. This represents a 0.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Tuesday, April 7th, Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.78, for a total value of $2,906.24.

SOPHiA GENETICS Trading Down 0.3%

SOPHiA GENETICS stock traded down $0.01 during trading on Wednesday, hitting $4.89. The company's stock had a trading volume of 64,929 shares, compared to its average volume of 188,371. The stock has a market capitalization of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The stock's fifty day moving average is $4.78 and its 200 day moving average is $4.68. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. As a group, equities research analysts predict that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS during the third quarter worth about $48,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the third quarter worth about $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS during the fourth quarter worth about $49,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Guggenheim upped their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research restated a "buy" rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.